Apogee Therapeutics
Apogee Therapeutics develops novel antibody therapeutics targeting key biological pathways to treat immunological and inflammatory disorders such as atopic dermatitis and asthma. The company aims to improve treatment efficacy and dosing flexibility in a market that currently lacks optimal solutions for these chronic conditions.
- Biotechnology
Funding
Raised to date
$483MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many immunological and inflammatory disorders, such as atopic dermatitis and asthma, lack sufficiently effective treatments and convenient dosing options, leaving a significant unmet need for patients. Current therapies often fail to provide optimal relief or require frequent administration, impacting patient quality of life.
Solution
Apogee Therapeutics is developing a pipeline of novel antibody therapeutics designed to target key biological pathways implicated in inflammatory and immunological diseases. These biologics aim to improve treatment efficacy and dosing flexibility compared to existing therapies, potentially reshaping the standard of care for conditions like atopic dermatitis, asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis. By focusing on well-established biological drivers and development pathways, Apogee seeks to provide differentiated treatment options for a range of dermatological, respiratory, and gastroenterological conditions.
Target Audience
The primary target audience includes individuals suffering from inflammatory and immunological disorders such as atopic dermatitis, asthma, COPD and eosinophilic esophagitis, as well as the healthcare providers who treat them.
Features
- Novel antibody therapeutics targeting validated biological pathways
- Focus on improving efficacy and dosing convenience
- Pipeline includes treatments for atopic dermatitis, asthma, COPD, and eosinophilic esophagitis
- Potential to address unmet needs in inflammatory and immunological diseases